![Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-4226264-1-150x150.jpg "Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI 1")
Federal Cannabis Rescheduling: Evidence-Based Policy Over Celebrity Opinion
The debate over federal cannabis rescheduling requires evidence-based policy decisions rather than celebrity-driven discourse. Current Schedule I classification restricts vital clinical research and creates legal barriers that complicate patient access…
FDA Cannabis Products Move from Schedule I to Schedule III Under New DEA Rule
The U.S. Department of Justice has proposed rescheduling FDA-approved cannabis-derived products from Schedule I to Schedule III, recognizing their medical utility while maintaining controlled substance oversight. This cannabis schedule III…
DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I
The U.S. Drug Enforcement Administration has placed CUMYL-PEGACLONE, a synthetic cannabinoid analog, into Schedule I of the Controlled Substances Act due to its high abuse potential and lack of accepted medical use. This CUMYL-PEGACLONE Schedule I…
DEA Places 2-Fluorodeschloroketamine in Schedule I Controlled Substances
The DEA has temporarily placed 2-fluorodeschloroketamine in Schedule I of the Controlled Substances Act, reflecting regulatory action against emerging synthetic ketamine analogs. This DEA Schedule I classification demonstrates the federal approach to…
Policy Watch: 20 Regulatory Updates — June 08, 2026
Policy WatchJune 08, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Cannabis policy priorities and public health- a survey of elected officials in California
This study reveals that among California elected officials, economic priorities dominate over health concerns. Despite cross-party consensus on youth packaging bans, implementation remains sparse.
Policy Watch: 10 Regulatory Updates — June 02, 2026
Policy WatchJune 02, 2026. 10 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Reclassification of marijuana opens doors for much-needed medical research … – The Conversation
The DEA's proposed reclassification of cannabis from Schedule I to Schedule III represents a watershed moment for medical research opportunities in cannabis medicine. This regulatory shift will remove decades-old barriers to rigorous clinical studies…
Cannabis Policy Shift Explained – Per NY Times
The cannabis rescheduling Trump policy is reshaping industry economics. Tax relief and investment may increase. But clinical care and evidence remain largely unchanged.
“We need to get educated”: lessons from physicians certifying cannabis as an alternative to opioids in the Illinois Opioid Alternative Patient Program.
A survey of Illinois physicians participating in the state's Opioid Alternative Patient Program revealed that cannabis as opioid alternative physician education remains a critical need. Even early adopter clinicians emphasized educational gaps as a…